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A B S T R A C T
Cardiac resynchronization therapy (CRT) achieved by biventricular pacing (CRT-P) 
has been proved to improve symptoms and prognosis of patients with refractory heart 
failure. Sudden cardiac death is quite common among patients with symptomatic heart 
failure and implantable cardioverter-defibrillator (ICD) therapy has been proved to 
effectively reduce sudden deaths in heart failure patients. Given the results of the 
recently published primary prevention trials and the high incidence of sudden car-
diac death among CRT-P recipients, CRT combined with backup defibrillator therapy 
(CRT-D) seems a logical therapeutic option in patients eligible for CRT. However, 
the apparent beneficial effects of such an appealing combination do not alleviate the 
skepticism about the unselected use of CRT-D therapy. This skepticism is largely re-
lated to the high cost of this method, to the limited availability of human and financial 
resources and to our inability to appropriately define the selection criteria for CRT 
candidates, which are expected to influence the clinicians’ decisions when confronted 
with the dilemma of providing CRT-D therapy for all patients eligible for CRT.
C A R d i A C  R e S y n C h R o n i z A T i o n  T h e R A p y
Heart failure has emerged as a cardinal public health problem that has been plaguing 
our society over several decades and poses a significant financial burden on our health 
care system. It is estimated that acute decompensated heart failure accounts for 2.9% 
of all emergency room visits, and that its prevalence is steadily increasing in epidemic 
proportions as well as in an age-dependent manner, reaching an incidence of almost 
10% in patients aged >65 years [1]. There has been considerable improvement in our 
therapeutic armamentarium over the years with significant benefit obtained from the 
use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers and 
β-blocking agents. However, there is still a large population of heart failure patients 
who remain refractory to current therapeutic approaches and this therapeutic gap 
has recently been bridged by the newer mode of electrical therapy known as cardiac 
resynchronization therapy (CRT), effected by biventricular pacing [2-3].
Asynchronous contraction due to cardiac conduction abnormalities, often described 
as cardiac dyssynchrony, reflected by the presence of left bundle branch block (LBBB) on 
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the electrocardiogram (ECG), occurring in 20-30% of patients 
afflicted by heart failure, has been documented to adversely 
affect the function of the failing heart [4]. Furthermore, it 
has been shown that cardiac dyssynchrony has an unfavorable 
influence on prognosis in patients with heart failure [5,6].
Cardiac resynchronization therapy, aims to improve the 
mechanical function of the failing heart. Biventricular pacing is 
an effective way to achieve CRT and restore electromechanical 
synchrony by simultaneously pacing at different sites of the 
heart, classically at the right ventricular apex and the lateral 
wall of the left ventricle. This is accomplished through per-
cutaneous techniques by inserting the left ventricular pacing 
lead via the coronary sinus and placing it into a lateral cardiac 
vein tributary. In a large number of studies, it is a consistent 
finding that biventricular pacing increases left ventricular 
ejection fraction and cardiac output and most importantly, 
improves quality of life, functional class and exercise capac-
ity in the majority of the treated patients [7-10]. In terms of 
pathophysiology, CRT has a unique characteristic among other 
therapies for heart failure. Its favorable influence on cardiac 
performance has not been associated with increased oxygen 
consumption, an issue of profound importance, especially in 
patients with ischemic cardiomyopathy [11]. These striking 
beneficial effects of CRT, had not been accompanied by any 
detectable survival benefit in the large number of small ran-
domized trials that were published during the initial period 
of biventricular pacing [7-10]. Of course, these studies were 
not designed to detect a survival benefit and thus, they were 
underpowered to study the effects of biventricular pacing on 
overall mortality (Table 1).
However, the lack of statistical significance should not be 
considered synonymous to the lack of clinical significance. 
In the case of CRT, this fact was firstly supported by a meta-
analysis of four large randomized trials, which showed that 
CRT therapy significantly reduced all-cause mortality (relative 
risk=0.77) [12]. Thereafter, the results of the two randomized 
studies having total mortality as their primary end-point, the 
COMPANION [13] and the CARE-HF [14] trials, verified 
the aforementioned findings and provided the necessary 
evidence for the revised recommendations and guidelines on 
CRT use for patients with symptomatic heart failure, which 
were recently published by the American Heart Association 
(AHA)/American College of Cardiology (ACC) [15] and by 
the European Society of Cardiology (ESC) [16].
The synopsis of these recommendations, shown in Table 2, 
is the result of accumulating data supporting the use of CRT, 
not only to improve symptoms and to decrease hospitaliza-
tions, but also to improve survival in patients with cardiac 
dyssynchrony (QRS ≥120 ms), low ejection fraction (≤35%), 
and dilated left ventricle (end-diastolic diameter ≥55 mm), who 
have persistently symptomatic heart failure despite optimal 
medical therapy (New York Heart Association-NYHA class 
III-IV).
However, the data that have provided the evidence for 
these recommendations should be considered in the context of 
their major limitation, which is the use of QRS duration (≥0.12 
sec) as the main criterion of cardiac dyssynchrony, reflecting 
our limited insight into the pathophysiological mechanisms 
of cardiac dyssynchrony and heart failure and thus, our no-
torious inability to efficiently detect those patients who will 
mostly benefit from CRT (responders). The existence of a 
variable proportion (20-30%) of patients not responding to 
biventricular pacing (non-responders) in all published studies 
possibly undervalues the survival benefit afforded by CRT and 
emphasizes the need for reevaluation of the inclusion criteria 
for biventricular pacing. It has been suggested that the use of 
the recently developed echocardiographic indices of cardiac 
dyssynchrony may improve appropriate selection of responders 
to CRT by excluding those patients, who, despite the prolonged 
duration of the QRS complex, do not present any detectable 
electromechanical dyssynchrony [17-23]. However, among 
the large randomized CRT trials, only CARE-HF included 
echocardiographic criteria of electromechanical dyssynchrony. 
Although the role of echocardiography for the selection of 
appropriate candidates for CRT is rapidly evolving, and the 
criteria adopted from the CARE-HF investigators (interven-
tricular mechanical delay and preejection aortic time) have lost 
their appeal in recent years, it is of interest that this was the 
first large-scale multicenter randomized study that resulted 
in significantly improved cardiac and all-cause mortality in 
the CRT treated arm.
Despite a plethora of data published during recent years, 
the use of CRT in a variety of patients and clinical conditions 
is still under investigation (Table 3). The main reason for this 
is not the inconsistent results from published studies, but the 
fact that the vast majority of studies that addressed specific 
indications for biventricular pacing were underpowered to 
provide mortality data, mainly due to the small number of study 
participants. Moreover, conclusions extrapolated by second-
ary analysis of data derived from the few larger studies, have 
TABle 1. Possible reasons for observed lack of survival 
benefit in initial CRT studies
1. These studies were not designed or powered to detect a survival
 benefit
2. Small number of studied patients
3. Limited follow-up period
4. Exclusive use of electrocardiographic criteria for CRT candi-
 dates
5. Lack of in-depth knowledge of CRT pathophysiology
6. Inability to detect non-responders
7. Technical issues (technology of coronary sinus pacing leads 
 and delivery systems, selection of appropriate cardiac vein, post 
 implantation optimization of programmed atrioventricular and 
 interventricular delays)
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TABle 2. Synopsis of the recently published reccomendations from AHA/ACC and ESC, concerning CRT in chronic 
heart failure patients.
patients’ characteristics Clinical  
end-point
Class and level 
of evidence
Ref.
ACC/AHA Guideline 
Update for Chronic 
Heart Failure
(2005 update)
• NYHA class III-IV
• LVEF ≤35%
• Sinus rhythm
• Symptoms despite optimal medical therapy 
• Cardiac dyssynchrony (currently defined as QRS >0.12 ms)
Symptoms,
Hospitalizations,
Mortality
I (A) 15
ESC guidelines for 
Chronic Heart Failure 
(2005 update)
• NYHA class III-IV
• Reduced LVEF
• Symptoms despite optimal medical therapy
• Cardiac dyssynchrony (QRS>0.12 ms)
Symptoms,
Hospitalizations
I (A) 16
Mortality I (B) 16
LVEF= left ventricular ejection fraction; NYHA= New York Heart Association
TABle 3. Clinical conditions where a recommendation 
for CRT is still precluded according to the AHA/ACC 
guidelines update 2005
1. Atrial fibrillation
2. Right bundle branch block (RBBB)
3. Pacemaker-induced dyssynchrony in case of pace-dependency
4. Existence of mechanical dyssynchrony in the absence of pro-
longed QRS duration
5. Co-existing right heart failure
6. NYHA II stage
rightfully been considered preliminary and need to be verified 
by specifically designed studies. However, the recommenda-
tions that have been precluded by the authors of the recently 
published guidelines due to the lack of solid evidence may 
be reasonable therapeutic choices for the individual patient 
in everyday practice. For instance, the decision to implant a 
biventricular pacemaker in a patient eligible for pacemaker 
therapy due to atrioventricular conduction abnormalities, 
and who has a prolonged PQ interval, a relatively narrow 
QRS complex, and suffers from severe, refractory to medi-
cal treatment heart failure, could be considered of profound 
benefit in selected cases, especially taking into consideration 
the unfavorable effects of pacemaker-induced dyssynchrony 
in patients with advanced heart failure and pace-dependency. 
However, such a policy has not been included in the recently 
published recommendations because it is not supported by a 
specifically designed large-scale randomized trial.
i m p l A n T A B l e  C A R d i o v e R T e R /
d e f i B R i l l A T o R  T h e R A p y
Sudden cardiac death is quite common among patients with 
symptomatic heart failure [24]. A number of studies conducted 
in post myocardial infarction patients at high risk predominantly 
due to impaired systolic function of the left ventricle (EMIAT, 
CAMIAT, TRACE, SWORD and DIAMOND-MI), have 
reported that the cumulative incidence of arrhythmic mortality 
reached about 5% at 1 year and about 9% at 2 years, whereas 
the incidence of non-arrhythmic cardiac death was about 4% 
and 7%, respectively [25-29]. The MERIT-HF trial including 
50% of patients with ischemic cardiomyopathy, reported an 
annual mortality rate of 11%, which was reduced to 7% in the 
metoprolol arm [30]. In symphon with a secondary analysis of the 
MERIT-HF data, the meta-analysis by Kjekshus et al., showed 
that patients with less severe heart failure are more likely to die 
suddenly compared to those at advanced NYHA stage [31].
It is of little doubt that patients with heart failure, previ-
ous cardiac arrest and/or documented sustained ventricular 
tachyarrhythmias, are at especially high risk and should be 
treated with an implantable cardioverter/defibrillator (ICD). In 
contrast, implantation of ICDs for primary prevention of sudden 
arrhythmic death in patients with heart failure symptoms has 
been considered an issue of additional complexity. Clinicians 
are aware of the fact that almost half of these patients present 
episodes of non-sustained ventricular tachycardia in routine 
ambulatory electrocardiographic (Holter) monitoring [32]. 
However, the positive predictive value of similar insensitive 
findings has been proved to be very low, seriously affecting 
our ability to accurately select those patients who are most 
likely to benefit from ICD therapy on an individualized basis. 
Until reliable genetic risk stratification and manipulation of 
arrhythmic background is widely available, risk stratification 
for arrhythmic death based solely on clinical and demographic 
criteria seems inevitable. In this context, the trials that investi-
gated the protective role of ICDs in large groups of patients with 
structural heart disease who have not presented documented 
life-threatening arrhythmias (primary prevention trials) have 
focused specifically on patients with heart failure symptoms 
and reduced left ventricular ejection fraction because of their 
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propensity for life-threatening arrhythmias. Although there 
have been a few studies that failed to detect any measurable 
beneficial effect of ICD therapy on mortality, the larger re-
cently published studies strongly support the mortality benefit 
afforded by ICD implantation for primary prevention of sudden 
cardiac death in heart failure patients.
A synopsis of published trials that have focused on the 
role of ICDs for the primary prevention of sudden cardiac 
death is presented in Table 5 [13,33-37] Based on these stud-
ies, the AHA/ACC guidelines for heart failure suggest that 
consideration of ICD implantation is recommended in patients 
with left ventricular ejection fraction less than 30% and mild 
to moderate symptoms of heart failure, and in whom survival 
with good functional capacity is otherwise anticipated to extend 
beyond one year [15]. In accordance with the AHA/ACC recom-
mendations, the respective ESC guidelines suggest that ICD 
implantation is reasonable in selected symptomatic patients 
with left ventricular ejection fraction <30-35%, not within 40 
days of a myocardial infarction [16]. The lateral cause refers to 
a recent study indicating that prophylactic implantation of an 
ICD within the first 40 days after an acute myocardial infarc-
tion does not confer any protection against sudden cardiac 
death [35]. Patients should also have had a revascularization 
procedure at least 3 months before they are considered for 
ICD implantation for primary prevention.
i m p l A n T A B l e  C A R d i o v e R T e R /
d e f i B R i l l A T o R S  i n  p A T i e n T S  w i T h 
A d v A n C e d  h e A R T  f A i l u R e  e l i g i B l e 
f o R  C A R d i A C  R e S y n C h R o n i z A T i o n 
T h e R A p y
One could hypothesize that, based on the recently pub-
TABle 4. Synopsis of the recently published reccomendations from AHA/ACC and ESC, concerning implantable 
cardioverter-defibrillator therapy in chronic heart failure patients.
Patients’ characteristics Clinical endpoint Class and level of evidence Ref.
ACC/AHA Guideline 
Update for Chronic 
Heart Failure
(2005 update)
• Secondary prevention
• Reduced LVEF
• Heart failure symptoms
Mortality I (A)
15
• Primary prevention
• Ischemic heart disease
• LVEF ≤30%
• NYHA stage II-III
• >40 days post MI
Mortality I (A)
• Primary prevention
• Nonischemic cardiomyopathy
• LVEF ≤30%
• NYHA stage II-III
Mortality I (B)
• Primary prevention
• Any cardiomyopathy
• LVEF 30-35%
• NYHA stage II-III
Mortality IIa (B)
ESC guidelines for 
Chronic Heart Failure 
(2005 update)
• Combined with CRT
• NYHA class III-IV
• LVEF ≤35%
• QRS duration >120 ms
• Symptoms despite optimal medical therapy
Morbidity and Mor-
tality 
IIa (B)
16
• Secondary prevention
• Reduced LVEF
• Heart failure symptoms
Mortality I (A)
• Primary prevention
• Selected symptomatic patients
• LVEF <30-35%
• >40 days post MI
Mortality I (A)
CRT= cardiac resynchronization therapy; LVEF= left ventricular ejection fraction; MI= myocardial infarction; NYHA= New York Heart 
Association
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TABle 5. Selected primary prevention trials of implantable cardioverter-defibrillator therapy in patients with heart 
failure.
Study patients
(n)
etiology of structural heart disease lvef
(%)
Relative risk for mortality
(iCd vs control)
p value Ref.
MADIT II 1232 IHD ≤30 0.69 (0.51-0.93) 0.007 33
CABG-PATCH 900 IHD (Plus late potentials) ≤35 1.07(0.81-1.42) 0.640 34
DINAMIT 674 IHD (<40 days post MI) ≤35 1.08 (0.76-1.55) 0.660 35
SCD-HeFT 2521 IHD/nonIHD ≤35 0.77 (0.62-0.96) 0.007 36
DEFINITE 458 nonIHD ≤35 0.65 (0.40-1.06) 0.080 37
COMPANION
(CRT-D study)
1520 IHD/nonIHD ≤35 0.50 (0.29-0.88) 0.010 13
CRT denotes cardiac resynchronization therapy, ICD implantable cardioverter defibrillator, IHD ischemic heart disease, MI myocardial infarction, 
LVEF left ventricular ejection fraction
lished studies and guidelines, the addition of ICD capability 
is crucial for the vast majority of patients eligible for CRT. 
Indeed, the majority of patients eligible for CRT could be 
included in the groups of patients eligible for ICD therapy, 
mainly because of the expanded indications of ICD therapy 
for primary prevention of sudden cardiac death in patients with 
heart failure of ischemic and of non-ischemic cardiomyopathy 
(Table 5). Furthermore, despite their differences regarding 
baseline characteristics of the studied patients, the selection 
criteria for the treated arms, and mortality at 12 months (19 vs 
12.6%, respectively), in both COMPANION and CARE-HF 
studies it was reported that one-third of deaths that occurred 
during the follow-up period in the CRT-treated patients were 
sudden [13-14]. Availability of back-up defibrillator therapy 
would have avoided the majority of these deaths. This plausible 
assumption was supported by the 55% reduction of risk for 
sudden cardiac death in the CRT-D compared to the CRT 
arm in the COMPANION study and was further validated by 
the fact that only 2.9% of the CRT-D treated patients in the 
COMPANION trial died suddenly, compared to 7% of the 
CRT treated patients in the CARE-HF study.
Despite the appeal of the accumulating evidence on the 
beneficial effects of back-up defibrillator therapy in CRT 
patients there is still plenty of room for skepticism when 
the clinicians consider CRT-D treatment for their patients, 
especially in the absence of documented life-threatening 
ventricular tachyarrhythmia and/or syncope of unknown etiol-
ogy. Evidence-based reduction of the mortality relative-risk 
afforded by ICD therapy is an important issue, but not the 
only one that should be taken into consideration.
R e A S o n S  o f  S K e p T i C i S m  f o R  T h e  w i d e R  u S e 
o f  C R T- d  T h e R A p y
Due to the inordinately increased cost incurred by the ICD 
therapy, but also because of the lack of firm and conclusive 
data from large randomized and controlled studies decisively 
supporting the use of ICD back-up in all patients eligible for 
CRT, there has been plenty of skepticism in recommending 
the general use of combined CRT-D therapy in all patients 
receiving CRT. Several of these reasons for skepticism and 
relative issues are detailed below:
 Recently published data from primary prevention trials have 
shown that the survival benefit of ICD therapy is enhanced 
in patients with low ejection fraction who are at NYHA 
functional class II-III [36]. In contrast, CRT therapy has 
been convincingly tested in patients at advanced NYHA 
stage (class III and IV).
 The AHA/ACC guidelines suggest that ICD should be 
considered in patients whose survival with good functional 
capacity is anticipated to extend beyond 1 year. However, 
there is no specific marker or prognostic tool for the clini-
cians, which could enable them to accurately define this 
subgroup of patients. Given that 12-month mortality in CRT 
candidates ranged from 12 to 19%, providing ICD therapy to 
all CRT candidates may imprudently extend this expensive 
therapy to patients with inevitably unfavorable prognosis 
[10-11]. In this subgroup of patients, relative-risk reduction 
attributed to defibrillator therapy, although possible, may 
not accurately reflect absolute survival benefit.
 Dr Feldman and colleagues [38] have published a cost-
effectiveness analysis of the therapeutic choices in the 
COMPANION trial. The authors concluded that for the 
COMPANION trial patients, the use of CRT-P (biven-
tricular pacing alone) and CRT-D (with ICD back-up) was 
associated with a cost-effectiveness ratio below the generally 
accepted landmarks for therapeutic interventions of $50,000 
per quality life-year (QALY) to $100,000 per QALY. Based 
on Medicare data to calculate the aforementioned costs, 
the authors suggested that the clinical benefits of CRT-P 
and CRT-D can be achieved at a reasonable cost. However, 
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these results, although well-defended, do not necessarily 
apply to the majority of the European countries, where 
the cost of the devices is generally higher and the cost 
of hospitalizations and drug therapy considerably lower. 
The excessive cost of defibrillator therapy in patients with 
poor prognosis should be considered in the context of lo-
cal individualized socioeconomic capabilities, which vary 
significantly among countries. Should medical practice 
vary accordingly? This is a difficult question exceeding 
the scope of this analysis. However, physicians should be 
aware that cost-effectiveness of medical practice is an issue 
of increasing importance in the industrialized world and 
that appropriate selection of candidates for CRT would 
actually increase the cost-effectiveness by eliminating the 
proportion of non-responders. Given this, in terms of cost-
effectiveness, backup defibrillator therapy may be accessible 
to a wider proportion of patients eligible for CRT.
 Although the COMPANION trial favored the CRT-D 
therapy versus the CRT-P therapy, this study was under-
powered to directly compare these two therapies. The 
follow up was limited to 14 months by study design and 
after the ninth month the survival curves were absolutely 
parallel. Dr Daubert et al. [39] rightfully claimed that only 
a specifically designed study with 1,300 patients per group 
and a follow-up period equivalent to that of the CARE-HF 
trial would have a statistical power of 90% to detect a 5% 
absolute relative risk reduction of death from any cause 
with the use of CRT-D compared with CRT alone. But, 
who would undertake such a study? Having said that, we 
have to admit that the core issue of this dilemma has not 
been definitively answered yet. On the other hand, medical 
practice should not be based exclusively on solid irrefutable 
evidence. In a variety of situations this would be a terrible 
waste of valuable human and financial resources.
 The implantation of CRT-P devices is a demanding and 
potentially hazardous procedure. The learning curve of 
operators is heavily dependent on the number of implan-
tations and thus, high-volume centers are expected to be 
better qualified for CRT therapy, limiting the availability of 
the therapy. Implantation of CRT-D is an issue of additive 
complexity. Peri-procedural complications are expected to 
be more frequent in CRT-D versus CRT-P patients. This 
is one more argument in favour of those who defend the 
use of backup defibrillator therapy exclusively for those 
who are most likely to benefit from it.
C o n C l u S i o n S
According to the published data from large-scale trials and 
in agreement with the recently published recommendations 
from both the AHA/ACC and the ESC, availability of backup 
defibrillator therapy in all patients eligible for CRT seems a 
logical therapeutic option (Figure 1). However, once again, 
reality tempers the optimism of the experts. Cost-effective-
ness, limited availability of human and financial recourses 
and our inability to appropriately define the selection criteria 
for CRT candidates are the main unresolved issues that are 
expected to restrain the unselected use of CRT-D therapy 
in CRT candidates. The technological and medical steps 
towards CRT-D therapy for all patients eligible for CRT 
have not been completed yet. Less expensive, smaller CRT 
devices and improved selection criteria for CRT candidates 
will definitely make the answer to our dilemma obvious. Be-
ing realistic rather than optimistic, these prerequisites are all 
expected in the near future. Indeed, we are in dire need of 
randomized controlled studies between CRT-P and CRT-D 
having all-cause mortality as their primary end-point so as to 
settle a poignant issue in cardiac resynchronization therapy 
in heart failure patients [40].
figuRe 1. This is a patient with a history of coronary bypass 
graft surgery in the remote past, who has now developed se-
vere left ventricular dysfunction and refractory heart failure. He 
has received a triple atrioventricular biventricular pacing sys-
tem with defibrillator back-up, which provides not only cardiac 
resynchronization therapy (CRT) but also protects the patient 
against sudden cardiac death. The second right ventricular pac-
ing lead was left in place when the pacemaker was upgraded to 
a CRT-D system. This complete set of electrical therapy, com-
bining the best of two worlds (enhancing pump function and ef-
fectively protecting against malignant ventricular tachyarrhyth-
mias), would be desirable for every heart failure patient, if it 
were not for the very high cost and if all the data from properly 
designed studies were conclusive. 
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